Table 1 CUBN positivity rates on multi-cancer TMA cohort (Cohort 1)
Cancer origin | N (912 total) | CUBN positive N (%a) |
|---|---|---|
Prostate | 57 | 0 (0) |
Colon | 59 | 0 (0) |
Breast | 60 | 0 (0) |
Stomach | 59 | 0 (0) |
Lung | 105 | 0 (0) |
Ovary | 60 | 0 (0) |
Endometrium | 59 | 0 (0) |
Cervix | 59 | 0 (0) |
Hepatocellular | 28 | 0 (0) |
Neuroendocrine | 30 | 0 (0) |
Sarcoma | 60 | 0 (0) |
Urothelial | 20 | 0 (0) |
Renal cell carc. | 39 | 22 (56) |
- ccRCC | 30 | 18 (60) |
- other | 9 | 4 (44) |
Lymphoma | 20 | 0 (0) |
Melanoma | 20 | 0 (0) |
Testis | 18 | 0 (0) |
Oesophagus | 22 | 0 (0) |
Thyroid | 18 | 0 (0) |
Head and Neck | 20 | 1 (5) |
Pancreas | 51 | 0 (0) |
Cholangiocarc. | 41 | 0 (0) |
Gall bladder carc. | 7 | 0 (0) |
CUBN specificityb | 100% | |
CUBN PPVb | 96% |